BRAF and melanoma: Melanomas most often harbor mutations that affect the Ser/Thr kinase BRAF (50%), the small GTPase NRAS (25%), or the negative regulator of RAS, neurofibromin 1 (NF1) (14%), resulting in increased RAS/mitogen-activated protein kinase (MAPK) signaling4.